Canada markets close in 6 hours 21 minutes

Celldex Therapeutics, Inc. (CLDX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
37.40+0.08 (+0.21%)
As of 09:38AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close37.32
Open36.62
Bid27.69 x 800
Ask38.50 x 800
Day's Range36.88 - 37.62
52 Week Range19.85 - 57.20
Volume30,111
Avg. Volume848,406
Market Cap1.749B
Beta (5Y Monthly)2.43
PE Ratio (TTM)N/A
EPS (TTM)-1.73
Earnings DateNov 07, 2022 - Nov 11, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est65.67
  • Zacks

    Celldex Therapeutics (CLDX) Reports Q2 Loss, Lags Revenue Estimates

    Celldex (CLDX) delivered earnings and revenue surprises of -34.88% and 53.43%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Celldex Reports Second Quarter 2022 Financial Results and Provides Corporate Update

    - Positive interim data from barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria presented at EAACI 2022 - - First patients dosed in Phase 2 chronic urticaria studies - HAMPTON, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the second quarter ended June 30, 2022 and provided a corporate update. “In late June, Celldex reported positive interim data from our ongoing Phase 1b study of barzolvolimab in chronic spontane

  • GlobeNewswire

    Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria

    HAMPTON, N.J., July 21, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in a Phase 2 clinical study of barzolvolimab for the treatment of the two most common forms of chronic inducible urticaria (CIndU) - cold urticaria (ColdU) and symptomatic dermographism (SD). Barzolvolimab is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity.